1
|
Ghasemzadeh MA, Mirhosseini-Eshkevari B. Unique and outstanding catalytic behavior of a novel MOF@COF composite as an emerging and powerful catalyst in the preparation of 2,3-dihydroquinazolin-4(1 H)-one derivatives. NANOSCALE ADVANCES 2023; 5:7031-7041. [PMID: 38059021 PMCID: PMC10696948 DOI: 10.1039/d3na00805c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 11/03/2023] [Indexed: 12/08/2023]
Abstract
The creation of an emerging porous structure using the hybridization of UiO-66-NH2-MOF, a zirconium-based metal-organic framework (MOF), with a covalent organic framework (COF) based on terephthaldehyde and melamine (UiO-66-NH2-MOF@COF), was assessed using SEM, XRD, EDX/mapping, FT-IR, BET, and TGA analyses. Using the obtained composite as a potential recoverable heterogeneous nanocatalyst, different aldehydes were condensed with isatoic anhydride and anilines or ammonium acetate under solvent-free conditions to create derivatives of 2,3-dihydroquinazolin-4(1H)-one. Examining the catalytic capabilities of the designed UiO-66-NH2-MOF@COF to efficiently produce 2,3-dihydroquinazolin-4(1H)-ones was a standout activity. Low catalyst loading, simple set-up, outstanding yields, and catalyst recoverability are all benefits of this research.
Collapse
Affiliation(s)
- Mohammad Ali Ghasemzadeh
- Department of Chemistry, Qom Branch, Islamic Azad University Post Box: 37491-13191 Qom I. R. Iran
| | | |
Collapse
|
2
|
Antitubercular, Cytotoxicity, and Computational Target Validation of Dihydroquinazolinone Derivatives. Antibiotics (Basel) 2022; 11:antibiotics11070831. [PMID: 35884084 PMCID: PMC9311641 DOI: 10.3390/antibiotics11070831] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/16/2022] [Accepted: 06/17/2022] [Indexed: 02/04/2023] Open
Abstract
A series of 2,3-dihydroquinazolin-4(1H)-one derivatives (3a–3m) was screened for in vitro whole-cell antitubercular activity against the tubercular strain H37Rv and multidrug-resistant (MDR) Mycobacterium tuberculosis (MTB) strains. Compounds 3l and 3m with di-substituted aryl moiety (halogens) attached to the 2-position of the scaffold showed a minimum inhibitory concentration (MIC) of 2 µg/mL against the MTB strain H37Rv. Compound 3k with an imidazole ring at the 2-position of the dihydroquinazolin-4(1H)-one also showed significant inhibitory action against both the susceptible strain H37Rv and MDR strains with MIC values of 4 and 16 µg/mL, respectively. The computational results revealed the mycobacterial pyridoxal-5′-phosphate (PLP)-dependent aminotransferase (BioA) enzyme as the potential target for the tested compounds. In vitro, ADMET calculations and cytotoxicity studies against the normal human dermal fibroblast cells indicated the safety and tolerability of the test compounds 3k–3m. Thus, compounds 3k–3m warrant further optimization to develop novel BioA inhibitors for the treatment of drug-sensitive H37Rv and drug-resistant MTB.
Collapse
|
3
|
Emam AM, Dahal A, Singh SS, Tosso RD, Ibrahim SM, El-Sadek M, Jois SD, Enriz RD, Kothayer H. Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC. Arch Pharm (Weinheim) 2021; 354:e2100281. [PMID: 34585758 DOI: 10.1002/ardp.202100281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 09/07/2021] [Accepted: 09/08/2021] [Indexed: 11/07/2022]
Abstract
Globally, lung cancer and tuberculosis are considered to be very serious and complex diseases. Evidence suggests that chronic infection with tuberculosis (TB) can often lead to lung tumors; therefore, developing drugs that target both diseases is of great clinical significance. In our study, we designed and synthesized a suite of 14 new quinazolinones (5a-n) and performed biological investigations of these compounds in Mycobacterium tuberculosis (MTB) and cancer cell lines. In addition, we conducted a molecular modeling study to determine the mechanism of action of these compounds at the molecular level. Compounds that showed anticancer activity in the preliminary screening were further evaluated in three cancer cell lines (A549, Calu-3, and BT-474 cells) and characterized in an epidermal growth factor receptor (EGFR) binding assay. Cytotoxicity in noncancerous lung fibroblast cells was also evaluated to obtain safety data. Our theoretical and experimental studies indicated that our compounds showed a mechanism of action similar to that of erlotinib by inhibiting the EGFR tyrosine kinase. In turn, the antituberculosis activity of these compounds would be produced by the inhibition of enoyl-ACP-reductase. From our findings, we were able to identify two potential lead compounds (5i and 5l) with dual activity and elevated safety toward noncancerous lung fibroblast cells. In addition, our data identified three compounds with excellent anti-TB activities (compounds 5i, 5l, and 5n).
Collapse
Affiliation(s)
- Aya M Emam
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Achyut Dahal
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA
| | - Sitanshu S Singh
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA
| | - Rodrigo D Tosso
- Pharmacy Department, Facultad de Química, Bioquímica y Farmacia, IMIBIO-CONICET, Universidad Nacional de San Luis, San Luis, Argentina
| | - Samy M Ibrahim
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Mohamed El-Sadek
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Seetharama D Jois
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA
| | - Ricardo D Enriz
- Pharmacy Department, Facultad de Química, Bioquímica y Farmacia, IMIBIO-CONICET, Universidad Nacional de San Luis, San Luis, Argentina
| | - Hend Kothayer
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| |
Collapse
|
4
|
Sakr A, Rezq S, Ibrahim SM, Soliman E, Baraka MM, Romero DG, Kothayer H. Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzyme Inhib Med Chem 2021; 36:1810-1828. [PMID: 34338135 PMCID: PMC8330735 DOI: 10.1080/14756366.2021.1956912] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Novel quinazolinones conjugated with indole acetamide (4a–c), ibuprofen (7a–e), or thioacetohydrazide (13a,b, and 14a-d) were designed to increase COX-2 selectivity. The three synthesised series exhibited superior COX-2 selectivity compared with the previously reported quinazolinones and their NSAID analogue and had equipotent COX-2 selectivity as celecoxib. Compared with celecoxib, 4 b, 7c, and 13 b showed similar anti-inflammatory activity in vivo, while 13 b and 14a showed superior inhibition of the inflammatory mediator nitric oxide, and 7 showed greater antioxidant potential in macrophages cells. Moreover, all selected compounds showed improved analgesic activity and 13 b completely abolished the pain response. Additionally, compound 4a showed anticancer activity in tested cell lines HCT116, HT29, and HCA7. Docking results were consistent with COX-1/2 enzyme assay results. In silico studies suggest their high oral bioavailability. The overall findings for compounds (4a,b, 7c, 13 b, and 14c) support their potential role as anti-inflammatory agents.
Collapse
Affiliation(s)
- Asmaa Sakr
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Samar Rezq
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.,Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.,Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS, USA.,Women's Health Research Center, University of Mississippi Medical Center, Jackson, MS, USA.,Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, MS, USA
| | - Samy M Ibrahim
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Eman Soliman
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Mohamed M Baraka
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Damian G Romero
- Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.,Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS, USA.,Women's Health Research Center, University of Mississippi Medical Center, Jackson, MS, USA.,Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, MS, USA
| | - Hend Kothayer
- Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| |
Collapse
|
5
|
Mass EB, Duarte GV, Russowsky D. The Quinazoline-Chalcone and Quinazolinone-Chalcone Hybrids: A Promising Combination for Biological Activity. Mini Rev Med Chem 2021; 21:186-203. [PMID: 32744973 DOI: 10.2174/1389557520666200730160325] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 12/26/2019] [Accepted: 04/26/2020] [Indexed: 11/22/2022]
Abstract
Quinazoline and/or chalcones derivatives are important targets in several areas of chemical sciences, mainly, in the medicinal chemistry and pharmaceutical research. The purpose of this review was to systematize the information available in the literature, including patents, regarding the benefits, exerted by the combination of these two pharmacophores into single molecules. These hybrid compounds can exhibit different biological activities, causing a synergistic or a new effect, compared to the individuals. The variability of biological activities includes anticancer, anti-Alzheimer, antiviral and antimicrobial activities, among others. Additionally, synthetic methodologies to prepare the different molecular architectures were discussed based on their similarities. The increasing number of publications indicates the importance of molecular hybridization in the field of drug discovery.
Collapse
Affiliation(s)
- Eduardo Bustos Mass
- Laboratorio de Sínteses Organicas, Instituto de Quimica, Universidade Federal do Rio Grande do Sul, Av. Bento Goncalves 9500, CEP 91501-970, Agronomia, Porto Alegre, RS, Brazil
| | - Gilmar Vieira Duarte
- Laboratorio de Sínteses Organicas, Instituto de Quimica, Universidade Federal do Rio Grande do Sul, Av. Bento Goncalves 9500, CEP 91501-970, Agronomia, Porto Alegre, RS, Brazil
| | - Dennis Russowsky
- Laboratorio de Sínteses Organicas, Instituto de Quimica, Universidade Federal do Rio Grande do Sul, Av. Bento Goncalves 9500, CEP 91501-970, Agronomia, Porto Alegre, RS, Brazil
| |
Collapse
|
6
|
Venugopala KN, Ramachandra P, Tratrat C, Gleiser RM, Bhandary S, Chopra D, Morsy MA, Aldhubiab BE, Attimarad M, Nair AB, Sreeharsha N, Venugopala R, Deb PK, Chandrashekharappa S, Khalil HE, Alwassil OI, Abed SN, Bataineh YA, Palenge R, Haroun M, Pottathil S, Girish MB, Akrawi SH, Mohanlall V. Larvicidal Activities of 2-Aryl-2,3-Dihydroquinazolin -4-ones against Malaria Vector Anopheles arabiensis, In Silico ADMET Prediction and Molecular Target Investigation. Molecules 2020; 25:molecules25061316. [PMID: 32183140 PMCID: PMC7144721 DOI: 10.3390/molecules25061316] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Revised: 03/09/2020] [Accepted: 03/11/2020] [Indexed: 12/14/2022] Open
Abstract
Malaria, affecting all continents, remains one of the life-threatening diseases introduced by parasites that are transmitted to humans through the bites of infected Anopheles mosquitoes. Although insecticides are currently used to reduce malaria transmission, their safety concern for living systems, as well as the environment, is a growing problem. Therefore, the discovery of novel, less toxic, and environmentally safe molecules to effectively combat the control of these vectors is in high demand. In order to identify new potential larvicidal agents, a series of 2-aryl-1,2-dihydroquinazolin-4-one derivatives were synthesized and evaluated for their larvicidal activity against Anopheles arabiensis. The in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the compounds were also investigated and most of the derivatives possessed a favorable ADMET profile. Computational modeling studies of the title compounds demonstrated a favorable binding interaction against the acetylcholinesterase enzyme molecular target. Thus, 2-aryl-1,2-dihydroquinazolin-4-ones were identified as a novel class of Anopheles arabiensis insecticides which can be used as lead molecules for the further development of more potent and safer larvicidal agents for treating malaria.
Collapse
Affiliation(s)
- Katharigatta N. Venugopala
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
- Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa;
- Correspondence:
| | - Pushpalatha Ramachandra
- Department of Chemistry, School of Applied Sciences, REVA University, Bangalore 560 064, India; (P.R.); (R.P.)
| | - Christophe Tratrat
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Raquel M. Gleiser
- CREAN-IMBIV (UNC-CONICET), Av. Valparaíso s.n., Córdoba, Argentina and FCEFyN, AV. Sarsfield 299, Universidad Nacional de Cordoba, Cordoba 5000, Argentina;
| | - Subhrajyoti Bhandary
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, Bhopal By-pass Road, Bhauri, Bhopal 462 066, Madhya Pradesh, India; (S.B.); (D.C.)
| | - Deepak Chopra
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, Bhopal By-pass Road, Bhauri, Bhopal 462 066, Madhya Pradesh, India; (S.B.); (D.C.)
| | - Mohamed A. Morsy
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
- Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia 61511, Egypt
| | - Bandar E. Aldhubiab
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Mahesh Attimarad
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Anroop B. Nair
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Nagaraja Sreeharsha
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Rashmi Venugopala
- Department of Public Health Medicine, University of KwaZulu-Natal, Howard College Campus, Durban 4001, South Africa;
| | - Pran Kishore Deb
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, P.O. Box 1, Amman 19392, Jordan; (P.K.D.); (S.N.A.); (Y.A.B.)
| | - Sandeep Chandrashekharappa
- Institute for Stem Cell Biology and Regenerative Medicine, NCBS, TIFR, GKVK, Bellary Road, Bangalore 560 065, India;
| | - Hany Ezzat Khalil
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
- Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt
| | - Osama I. Alwassil
- Department of Pharmaceutical Sciences, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia;
| | - Sara Nidal Abed
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, P.O. Box 1, Amman 19392, Jordan; (P.K.D.); (S.N.A.); (Y.A.B.)
| | - Yazan A. Bataineh
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, P.O. Box 1, Amman 19392, Jordan; (P.K.D.); (S.N.A.); (Y.A.B.)
| | - Ramachandra Palenge
- Department of Chemistry, School of Applied Sciences, REVA University, Bangalore 560 064, India; (P.R.); (R.P.)
| | - Michelyne Haroun
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Shinu Pottathil
- Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia;
| | - Meravanige B. Girish
- Department of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia;
| | - Sabah H. Akrawi
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (C.T.); (M.A.M.); (B.E.A.); (M.A.); (A.B.N.); (N.S.); (H.E.K.); (M.H.); (S.H.A.)
| | - Viresh Mohanlall
- Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa;
| |
Collapse
|
7
|
Alipour M, Hossaini Z, Khaksar S, Rostami-Charati F. 3,5-Bis(trifluoromethyl) Phenylammonium triflate(BFPAT) as a Novel Organocatalyst for the Efficient Synthesis of 2,3-dihydroquinazolin-4(1H)-one Derivatives. Curr Org Synth 2020; 17:40-45. [PMID: 32103716 DOI: 10.2174/1570179417666191218115126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Revised: 11/21/2019] [Accepted: 12/16/2019] [Indexed: 11/22/2022]
Abstract
AIMS AND OBJECTIVES A one-pot synthesis of 2,3-dihydroquinazolin-4(1H)-one derivatives by threecomponent cyclo-condensation of isatoic anhydride, aldehydes and amine or ammonium acetate has been developed using 3,5-Bis(trifluoromethyl) phenylammonium triflate (BFPAT) as a new organocatalyst. MATERIALS AND METHODS All of the obtained products are known compounds and identified by IR, 1HNMR, 13CNMR and melting points. RESULTS A wide variety of structurally different aldehydes reacted easily and rapidly to result in the relating 2,3-dihydroquinazolin-4(1H)-ones in good to excellent yield. CONCLUSION We have demonstrated an extremely effective and new process for synthesizing 2,3- dihydroquinazolin-4(1H)-ones employing BFPAT as a novel organocatalyst in one-pot fashion.
Collapse
Affiliation(s)
- Mandana Alipour
- Department of Chemistry, Islamic Azad University, Qaemshahr Branch, Qaemshahr, Iran
| | | | - Samad Khaksar
- Department of Chemistry, Islamic Azad University, Ayatollah Amoli Branch, Amol, Iran.,Department of Chemistry, School of Science and Technology, The University of Georgia, Tbilisi, Georgia
| | - Faramarz Rostami-Charati
- Department of Chemistry, Faculty of Science, Gonbad Kavous University, P.O. Box 163, Gonbad Kavous, Iran.,Research Center for Conservation of Culture Relics (RCCCR), Research Institute of Cultural Heritage & Tourism, Tehran, Iran
| |
Collapse
|
8
|
Kharmawlong GK, Nongrum R, Chhetri B, Rani JWS, Rahman N, Yadav AK, Nongkhlaw R. Green and efficient one-pot synthesis of 2,3-dihydroquinazolin-4(1H)-ones and their anthelmintic studies. SYNTHETIC COMMUN 2019. [DOI: 10.1080/00397911.2019.1639754] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- George Kupar Kharmawlong
- Department of Chemistry, Centre for Advances Studies, North-Eastern Hill University, Shillong, India
| | - Ridaphun Nongrum
- Department of Chemistry, Centre for Advances Studies, North-Eastern Hill University, Shillong, India
| | - Bhusan Chhetri
- Department of Zoology, North-Eastern Hill University, Shillong, India
| | - Jims World Star Rani
- Department of Chemistry, Centre for Advances Studies, North-Eastern Hill University, Shillong, India
| | - Noimur Rahman
- Department of Chemistry, Centre for Advances Studies, North-Eastern Hill University, Shillong, India
| | - Arun Kumar Yadav
- Department of Zoology, North-Eastern Hill University, Shillong, India
| | - Rishanlang Nongkhlaw
- Department of Chemistry, Centre for Advances Studies, North-Eastern Hill University, Shillong, India
| |
Collapse
|